From Investing.com:



Wall Street is closely monitoring Biogen’s potential for a major rebound following a recent downturn. Biogen’s stock has been declining due to concerns about its flagship Alzheimer’s drug. The company is awaiting FDA approval for the drug, which has seen mixed results in clinical trials. However, with the potential for positive news and market speculation, Wall Street is eyeing Biogen for potential trading opportunities. Day traders should keep a close eye on Biogen’s developments and news regarding its Alzheimer’s drug for potential short-term trading opportunities.



Read more: Pro Research: Wall Street dives into Biogen’s prospects